Johnson & Johnson Reports Earnings, Notably Lowers EOY Outlook
Johnson & Johnson reported a miss on its Q1 earnings just shy of analyst expectations. The pharmaceutical giant also noted that it has an excess of COVID-19 vaccines and that it will be lowering its end-of-year earnings outlook for 2022.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
